Ann: Notice of Extraordinary General Meeting/Proxy Form, page-53

Could be anytime but I think CHM 1101 will be first cab off the rank. The 4th cohort of phase 1A were dosed March 2023 and we haven't heard anything from them. I emailed the company a week or so ago asking whether they planned on updating the market on their progress or waiting for phase 1B data, they replied and gave me nothing.

We haven't got word the Case Western trial is back on after it's hiatus. Jen did say in the last Webinar they were close to continuing, not sure if they'll let the market know or not. No idea when they will update the market with new data, hopefully sometime this year.

The ADVENT-AML is getting towards the back end of staggering patients but I'm not expecting any data until the back end of the year.

CHM 0201 should be getting into the clinic any day/week now. Complete eradication of all tumors within a month and no relapse. The early data here will be very telling. Looks to me like Jen leaving and this new 800 million placement revolves around getting CHM 2101 to the clinic. Time will tell